Abstract
Background: The INBUILD trial enrolled patients with progressive fibrosing ILDs other than IPF. It is unclear whether, as observed in patients with IPF, patients with fibrosing ILDs who have worse scores on patient-reported outcomes assessing symptoms or health-related quality of life (HRQL) are at greater risk of ILD progression.
Aim: To assess associations between patient-reported outcomes at baseline and progression of fibrosing ILDs in the INBUILD trial.
Methods: Associations between the King's Brief ILD (K-BILD) questionnaire total score and Living with Pulmonary Fibrosis (L-PF) questionnaire symptoms dyspnoea domain score at baseline and time to ILD progression (absolute decline in FVC ≥10% predicted) or death during the INBUILD trial were assessed using Cox’s regression models.
Results: At baseline, mean (SD) K-BILD total and L-PF symptoms dyspnoea domain scores were 52.4 (10.5) (n=662) and 21.7 (18.0) (n=652), respectively, on scales of 0–100. Median exposure to trial drug was 17.4 months. In both treatment groups, baseline K-BILD total scores or L-PF symptoms dyspnoea domain scores that indicated worse HRQL were associated with a higher risk of ILD progression or death during the trial (Figure).
Conclusions: In patients with progressive fibrosing ILDs, worse scores on patient-reported outcomes are associated with a higher risk of ILD progression or death.
Footnotes
Cite this article as: European Respiratory Journal 2021; 58: Suppl. 65, PA3748.
This abstract was presented at the 2021 ERS International Congress, in session “Prediction of exacerbations in patients with COPD”.
This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only).
- Copyright ©the authors 2021
